The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history, physical examination, and laboratory tests.
Body mass index within the range 18.5 to 39 kg/m2 (inclusive).
Female participants of childbearing potential may be enrolled in the study if not pregnant or breastfeeding, subject to other criteria specified in the study protocol.
History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic, or any components of an mRNA vaccine or therapeutic.
History of participation in a prior vaccine study for pathogens causing Ebola virus disease.
History of confirmed or suspected filovirus exposure or infection or travel to an impacted area within 1 month prior to the Screening Visit (e.g. Ebola Zaire, Sudan, BDBV, and Marburg).
Other conditions that in the Investigator's opinion could interfere with interpretation of study results or limit the participant's participation in the study.
6
Treatment groupsSee each treatment group below.